Vanguard Group Inc. Raises Holdings in AbbVie Inc. $ABBV

Vanguard Group Inc. increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 0.3% during the 3rd quarter, Holdings Channel reports. The fund owned 177,747,261 shares of the company’s stock after purchasing an additional 448,554 shares during the quarter. AbbVie makes up about 0.6% of Vanguard Group Inc.’s investment portfolio, making the stock its 20th largest position. Vanguard Group Inc. owned about 0.10% of AbbVie worth $41,155,601,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Ellenbecker Investment Group increased its holdings in shares of AbbVie by 0.8% during the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after purchasing an additional 44 shares in the last quarter. Security National Bank of Sioux City Iowa IA grew its position in AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after buying an additional 45 shares during the period. Matthew Goff Investment Advisor LLC increased its holdings in AbbVie by 0.3% in the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock valued at $4,066,000 after buying an additional 45 shares in the last quarter. Centennial Wealth Advisory LLC raised its position in shares of AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after acquiring an additional 45 shares during the period. Finally, Willner & Heller LLC raised its position in shares of AbbVie by 0.6% in the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock worth $1,759,000 after acquiring an additional 46 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ABBV. BMO Capital Markets restated an “outperform” rating and set a $258.00 target price on shares of AbbVie in a research report on Thursday, January 15th. Morgan Stanley raised their price objective on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Piper Sandler restated an “overweight” rating and issued a $289.00 price objective (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Finally, Citigroup dropped their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.00.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

AbbVie Price Performance

Shares of NYSE:ABBV opened at $231.57 on Monday. The business’s 50 day moving average price is $223.56 and its 200-day moving average price is $221.07. The firm has a market capitalization of $409.28 billion, a PE ratio of 98.12, a P/E/G ratio of 0.81 and a beta of 0.35. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the prior year, the company earned $2.16 EPS. The firm’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.